Lead Discovery Technologies, Geneva Research Center, Merck Serono SA, 9 Chemin des Mines CH-1202 Geneva, Switzerland.
Expert Opin Drug Discov. 2010 Jan;5(1):51-63. doi: 10.1517/17460440903493431.
Microfluidic electrophoretic mobility shift assays are becoming increasingly popular with screening groups throughout the pharmaceutical industry due to their excellent data quality and target flexibility.
This review summarizes our experience of the microfluidic electrophoretic mobility shift technique at Merck Serono as well as from the published literature. We assess the advantages and limitations of electrophoretic mobility shift assays in this context.
Published literature on the topic is scarce. The reader will gain an insight into the techniques and issues with the use of this technology in a pharmaceutical setting.
This technology has reached maturity, providing reliable and robust results. Current limitations are the lower-than-desired throughput capacity for primary screening campaigns, and its current restriction to enzyme classes catalyzing a significant change in mass/charge of the substrate.
由于其出色的数据质量和目标灵活性，微流控电泳迁移率变动分析在制药行业的各个筛选小组中越来越受欢迎。
本篇综述总结了我们在默克雪兰诺（Merck Serono）应用微流控电泳迁移率变动技术的经验，以及来自已发表文献的经验。我们评估了在这种情况下电泳迁移率变动分析的优势和局限性。
关于该主题的已发表文献很少。读者将深入了解该技术以及在制药环境中使用该技术的技术问题和挑战。
该技术已经成熟，能够提供可靠和稳健的结果。目前的限制是用于初步筛选活动的通量能力低于预期，以及其目前仅限于催化底物质量/电荷发生显著变化的酶类。
